Effect of aldose reductase inhibitor on fluorescein angiographic lesions in galactose-fed dogs

E. Chew, F. Ferris, Peter F Kador, M. Wyman, N. Remaley, M. Podgor

Research output: Contribution to journalArticle

Abstract

Purpose. To evaluate the effects of aldose reductase inhibitor on the diabetic-like retinopathy induced by galactose feeding in dogs. Methods. At 3 months of age, 20 male beagle dogs were rendered aphakic bilaterally. At 9 months of age, 12 dogs were fed a 30% galactose diet (control group) and 8 were fed a 30% galactose diet including an aldose reductase inhibitor Eisai M79175 (treatment group). After 34 months of galactose feeding, the treated dogs were placed on a normal diet and the aldose reductase inhibitor was discontinued. Stereoscopic fundus photographs and fluorescein were performed in a standardized fashion at baseline and at 6 month intervals. The photographic data, graded by a masked reader, was assessed for the development of retinal hemorrhages, the degree of retinal nonperfusion and the presence of retinal neovascularization. Results. Retinal hemorrhages first appeared at 24 months and 48 months in the control group and the treatment group, respectively. By 60 months of follow-up, 100% of the controls developed nonperfusion and only 20% of the treated group developed nonperfusion. The rates of progression of nonperfusion and the development of neovascularization were significantly higher in the control group than in the treated group (p<0.001). Conclusions. Aldose reductase inhibitor is effective in significantly delaying the onset of diabetic-like retinopathy in dogs on galactose feed.

Original languageEnglish (US)
JournalInvestigative Ophthalmology and Visual Science
Volume37
Issue number3
StatePublished - Feb 15 1996

Fingerprint

Aldehyde Reductase
Fluorescein
Galactose
Dogs
Retinal Hemorrhage
Diabetic Retinopathy
Diet
Control Groups
Retinal Neovascularization

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Effect of aldose reductase inhibitor on fluorescein angiographic lesions in galactose-fed dogs. / Chew, E.; Ferris, F.; Kador, Peter F; Wyman, M.; Remaley, N.; Podgor, M.

In: Investigative Ophthalmology and Visual Science, Vol. 37, No. 3, 15.02.1996.

Research output: Contribution to journalArticle

@article{c703b33b1c674a2184c4a3e7a77dff37,
title = "Effect of aldose reductase inhibitor on fluorescein angiographic lesions in galactose-fed dogs",
abstract = "Purpose. To evaluate the effects of aldose reductase inhibitor on the diabetic-like retinopathy induced by galactose feeding in dogs. Methods. At 3 months of age, 20 male beagle dogs were rendered aphakic bilaterally. At 9 months of age, 12 dogs were fed a 30{\%} galactose diet (control group) and 8 were fed a 30{\%} galactose diet including an aldose reductase inhibitor Eisai M79175 (treatment group). After 34 months of galactose feeding, the treated dogs were placed on a normal diet and the aldose reductase inhibitor was discontinued. Stereoscopic fundus photographs and fluorescein were performed in a standardized fashion at baseline and at 6 month intervals. The photographic data, graded by a masked reader, was assessed for the development of retinal hemorrhages, the degree of retinal nonperfusion and the presence of retinal neovascularization. Results. Retinal hemorrhages first appeared at 24 months and 48 months in the control group and the treatment group, respectively. By 60 months of follow-up, 100{\%} of the controls developed nonperfusion and only 20{\%} of the treated group developed nonperfusion. The rates of progression of nonperfusion and the development of neovascularization were significantly higher in the control group than in the treated group (p<0.001). Conclusions. Aldose reductase inhibitor is effective in significantly delaying the onset of diabetic-like retinopathy in dogs on galactose feed.",
author = "E. Chew and F. Ferris and Kador, {Peter F} and M. Wyman and N. Remaley and M. Podgor",
year = "1996",
month = "2",
day = "15",
language = "English (US)",
volume = "37",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of aldose reductase inhibitor on fluorescein angiographic lesions in galactose-fed dogs

AU - Chew, E.

AU - Ferris, F.

AU - Kador, Peter F

AU - Wyman, M.

AU - Remaley, N.

AU - Podgor, M.

PY - 1996/2/15

Y1 - 1996/2/15

N2 - Purpose. To evaluate the effects of aldose reductase inhibitor on the diabetic-like retinopathy induced by galactose feeding in dogs. Methods. At 3 months of age, 20 male beagle dogs were rendered aphakic bilaterally. At 9 months of age, 12 dogs were fed a 30% galactose diet (control group) and 8 were fed a 30% galactose diet including an aldose reductase inhibitor Eisai M79175 (treatment group). After 34 months of galactose feeding, the treated dogs were placed on a normal diet and the aldose reductase inhibitor was discontinued. Stereoscopic fundus photographs and fluorescein were performed in a standardized fashion at baseline and at 6 month intervals. The photographic data, graded by a masked reader, was assessed for the development of retinal hemorrhages, the degree of retinal nonperfusion and the presence of retinal neovascularization. Results. Retinal hemorrhages first appeared at 24 months and 48 months in the control group and the treatment group, respectively. By 60 months of follow-up, 100% of the controls developed nonperfusion and only 20% of the treated group developed nonperfusion. The rates of progression of nonperfusion and the development of neovascularization were significantly higher in the control group than in the treated group (p<0.001). Conclusions. Aldose reductase inhibitor is effective in significantly delaying the onset of diabetic-like retinopathy in dogs on galactose feed.

AB - Purpose. To evaluate the effects of aldose reductase inhibitor on the diabetic-like retinopathy induced by galactose feeding in dogs. Methods. At 3 months of age, 20 male beagle dogs were rendered aphakic bilaterally. At 9 months of age, 12 dogs were fed a 30% galactose diet (control group) and 8 were fed a 30% galactose diet including an aldose reductase inhibitor Eisai M79175 (treatment group). After 34 months of galactose feeding, the treated dogs were placed on a normal diet and the aldose reductase inhibitor was discontinued. Stereoscopic fundus photographs and fluorescein were performed in a standardized fashion at baseline and at 6 month intervals. The photographic data, graded by a masked reader, was assessed for the development of retinal hemorrhages, the degree of retinal nonperfusion and the presence of retinal neovascularization. Results. Retinal hemorrhages first appeared at 24 months and 48 months in the control group and the treatment group, respectively. By 60 months of follow-up, 100% of the controls developed nonperfusion and only 20% of the treated group developed nonperfusion. The rates of progression of nonperfusion and the development of neovascularization were significantly higher in the control group than in the treated group (p<0.001). Conclusions. Aldose reductase inhibitor is effective in significantly delaying the onset of diabetic-like retinopathy in dogs on galactose feed.

UR - http://www.scopus.com/inward/record.url?scp=33750156719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750156719&partnerID=8YFLogxK

M3 - Article

VL - 37

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -